Schimmelpennink Evert B. 4

4 · Contineum Therapeutics, Inc. · Filed Jun 26, 2026

AI-generated summary of this filing

Updated Jun 26, 2026

Contineum (CTNM) Director Evert Schimmelpennink Receives 19,000-Share Option Award

What Happened

Evert B. Schimmelpennink, a member of Contineum Therapeutics' board of directors, received a grant of options to acquire 19,000 shares of the company's Class A common stock on June 26, 2026. The Form 4 lists the transaction as an award (transaction code A) and shows $0.00 in the price column, indicating a derivative option grant rather than a cash purchase. No immediate cash value was exchanged in the filing.

Key Details

Transaction date: 2026-06-26 (Form 4 filed the same date).
Transaction type/code: Grant/Award (A) — stock options (derivative).
Shares/units: Options covering 19,000 shares.
Price reported on Form 4: $0.00 (reflects grant; not an exercise price).
Vesting: Options vest in full on the earlier of (i) June 26, 2027 (one-year anniversary) or (ii) the next regular annual meeting of stockholders, subject to continuous service (per footnote).
Shares owned after transaction: Not specified in the Form 4 filing.
Filing timeliness: Reported same day as the transaction (timely).

Context

This is a routine non-employee director compensation grant under Contineum’s 2024 Equity Incentive Plan and the company’s Non-Employee Director Compensation Program (automatic annual grant for continuing non-employee directors). As an unexercised option award, it does not represent an immediate purchase or sale of shares. Retail investors should view this as standard board compensation rather than a direct insider buy or sell signal.

Form 4

Period: 2026-06-26

Director

Transactions

Award
Stock Option (right to buy)
[F1]
2026-06-26+19,000→ 19,000 total
Exercise: $14.19Exp: 2036-06-25→ Class A Common Stock (19,000 underlying)

Footnotes (1)

[F1]Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

Signature

/s/ Peter Slover, Attorney-in-Fact|2026-06-26

1 file